Veru, Inc. (VERU) FDA Approval Reinforces View Stock Undervalued - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Brandon Folkes reiterated an Overweight rating and $24.00 price target on Veru, Inc. (NASDAQ: VERU) following FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
